Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that today Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) of the Company, as set out below, have been acquired for the Non-Executive Directors, being the part of their total fees that are paid in securities for the period of service from January 1 to March 31, 2014.
|Type of Security (1)||Number of Securities|
|Dr. Steven Gillis||ADSs||57|
|Dr. David Ginsburg||ADSs||54|
(1) One ADS is equql to three Shares
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at prices of £29.9876 per Share and $147.90 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Deputy Company Secretary
For further information please contact:
+1 781 482 0733
+1 781 482 0999
+44 1256 894157
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
Click here for the PDF version of this press release.